GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the company’s management team will participate in and present at 1×1 Meeting at the following investor conference:
- HC Wainwright 7th Annual NASH Investor Conference (Virtual Conference)
Tuesday, October 24, 2023
Lecture at 10:00 a.m. Eastern Time
- HC Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
Wednesday, October 25, 2023
Fireside Chat at 3:00 pm Eastern Time
These sessions will be webcast live and can be viewed by visiting the Events section of Altimmune’s website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapies to treat obesity and liver disease. The company’s lead product candidate, pemvidutide, is a dual GLP-1/glucagon receptor agonist being developed to treat obesity and NASH. Additionally, Altimmune is developing HepTcell™, an immunotherapy designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. LinkedIn
Follow @AltimmuneInc Twitter
Altimmune investor contact information:
Richard Eisenstat
CFO
Phone: 240-654-1450
reisenstadt@altimmune.com
Media contact information:
Danielle Canty
evoke canal
Phone: 619-826-4657
danielle.cantey@evokegroup.com
